Please Wait
Applying Filters...
menu
    • menu
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Elraglusib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actuate Highlight Elraglusib Data in Metastatic Pancreatic Cancer
    Actuate Highlight Elraglusib Data in Metastatic Pancreatic Cancer

    01 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/01/3304175/0/en/actuate-therapeutics-announces-asco-poster-presentations-demonstrating-compelling-clinical-and-biomarker-data-for-elraglusib-in-first-line-metastatic-pancreatic-cancer.html

    GLOBENEWSWIRE
    01 Jun 2026
    Share Share
    Actuate Therapeutics Gets IND Clearance for Oral Elraglusib
    Actuate Therapeutics Gets IND Clearance for Oral Elraglusib

    11 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/11/3291744/0/en/actuate-therapeutics-announces-fda-clearance-of-ind-for-oral-elraglusib-and-strategic-initiatives-to-advance-the-elraglusib-development-program.html

    GLOBENEWSWIRE
    11 May 2026
    Share Share
    Actuate Therapeutics Reveals Doubling Survival Rate
    Actuate Therapeutics Reveals Doubling Survival Rate

    14 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/14/3273413/0/en/Actuate-Therapeutics-Announces-Nature-Medicine-Publication-of-Clinical-Trial-Results-Showing-Doubling-of-the-Rate-of-Survival-with-Elraglusib-Plus-Chemotherapy-in-Previously-Untrea.html

    GLOBENEWSWIRE
    14 Apr 2026
    Share Share
    Actuate Therapeutics Set For $200M+ Pediatric Priority Review
    Actuate Therapeutics Set For $200M+ Pediatric Priority Review

    24 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-24/actuate-therapeutics-poised-for-potential-200mplus-pediatric-priority-review-vouchers-and-transformat

    PHARMIWEB
    24 Mar 2026
    Share Share
    Actuate Studies Elraglusib With RAS Inhibitors
    Actuate Studies Elraglusib With RAS Inhibitors

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251848/0/en/Actuate-Therapeutics-Launches-Strategic-Research-Initiative-to-Combine-Elraglusib-with-RAS-Inhibitors.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Actuate Expands Pipeline with Elraglusib Ph 1/2 Program in Cancer
    Actuate Expands Pipeline with Elraglusib Ph 1/2 Program in Cancer

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222807/0/en/Actuate-Therapeutics-Announces-Plans-to-Expand-Clinical-Pipeline-Advancing-Elraglusib-Tablet-into-a-Phase-1-2-Clinical-Program-in-Refractory-Cancers.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.